Ciprofloxacin - NDSRI's
References
FAQ's
References
- Grohe, Klaus; Zeiler, Hans Joachim; Metzger, Karl, 7-amino-1-cyclopropyl-4-oxo-1, 4-dihydro-quinoline-and naphthyridine-3-carboxylic acids and antibacterial agents containing these compounds, US4670444B1, May 29, 1984, Bayer A.-G., Federal Republic of Germany (https://patents.google.com/patent/US4670444B1/en)
- Gau, W.; Ploschke, H. J.; Schmidt, K.; Weber, B., Determination of ciprofloxacin (BAY o 9867) in biological fluids by high-performance liquid chromatography, Journal of Liquid Chromatography, Volume: 8, Issue: 3, Pages: 485-97, 1985, DOI: (10.1080/01483918508067095)
Frequently Asked Questions
2. How do Ciprofloxacin impurities and degradation products form in the Ciprofloxacin drug?
Ciprofloxacin impurities originate from the by-products of the drug synthesis—the degradation products form due to decarboxylation, hydroxylation, and photolysis.
3. Which analytical method identifies the Ciprofloxacin impurities?
Capillary zone electrophoresis (CZE) is the method that identifies the Ciprofloxacin impurities.
4. Why control of residual solvents is necessary in Ciprofloxacin drug substance?
Residual solvents can be toxic and carcinogenic, so it is critical to remove them from the Ciprofloxacin drug substance.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.